Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Argus Health

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,630,162

« Back to Dashboard

Which drugs does patent 6,630,162 protect, and when does it expire?

Patent 6,630,162 protects DETROL LA and is included in one NDA. There has been one Paragraph IV challenge on Detrol LA.

Protection for DETROL LA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 6,630,162

Title: Pharmaceutical formulation and its use
Abstract:The invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the formulation exhibits a controlled in vitro release of the active ingredient in phosphate buffer at pH 6.8 of not less than about 80% after 18 hours, and after oral administration to a patient is capable of maintaining a substantially constant serum level of the active moiety or moieties for 24 hours. The invention also relates to the use of the pharmaceutical formulation for treating overactive bladder and gastrointestinal disorders.
Inventor(s): Nilvebrant; Lisbeth (Bromma, SE), Hallen; Bengt (Sollentuna, SE), Olsson; Birgitta (Stenhamra, SE), Strombom; Jan (Vattholm, SE), Gren; Torkek (Kalamazoo, MI), Ringberg; Anders (Stockholm, SE), Wikberg; Martin (Kullavik, SE)
Assignee: Pharmacia AB (Stockholm, SE)
Application Number:09/708,428
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Pharmacia And UpjohnDETROL LAtolterodine tartrateCAPSULE, EXTENDED RELEASE;ORAL021228-001Dec 22, 2000ABRXYesNo► Subscribe► Subscribe► SubscribeY
Pharmacia And UpjohnDETROL LAtolterodine tartrateCAPSULE, EXTENDED RELEASE;ORAL021228-002Dec 22, 2000ABRXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,630,162

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden0000782Mar 09, 2000

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
US Army
Daiichi Sankyo
Harvard Business School
Cantor Fitzgerald
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: